1. The Battle for Genzyme, The Future of Orphan Diseases
What are the implication of the Genzyme acquisition for the biotech industry? Why is Big Pharma buying Big Biotech? Is ‘Orphan Disease’ just a buzz word, or is there increasing fundamental rationale for orphan drug development?
2. Uncertainty & the FDA. Are Investors Being Driven Away from the Biotech Industry?
The system needs an overhaul, a comprehensive fix, explains Dennis Purcell. While the biological risks are understood and accepted, the regulatory risk are not. We need models that take regulatory uncertainty out of the equation.
3. How Obama-care is Affecting the Mindset of Investors. Most Positive and Negative Events for 2010.
While it is not a reason not to invest, the healthcare reform has made reimbursement an essential consideration in drug development. The FDA’s approval of Dendreon Provenge, and J&J’s billion dollar acquisition of Cougar Biotech are some of the highlights of 2010 for the Biotech Industry; the FDA would have to be the low point.
4. What is Driving Emerging Markets? What Does China Need from Us?
Increased regulatory uncertainty in the U.S. contributes to the view that emerging markets can’t be ignored anymore. With a rapidly growing healthcare market, what does China need from us?
5. The pressure for 2-4 Year Exits. Predictions for 2011.
With significant pressure from investors for 2-4 year exits, the need for liquidity is so high that everyone is looking for exits. How will that affect innovative technologies and platforms that would require 10years and billions of dollars to get to get to market? How can we get the public involved? What are some of the expectations for 2011?
This interview was conducted at the NASDAQ Marketsite, on December 15th, 2010, in New York City.
Featuring:
Related Videos: